Effect of mifentidine, a new H2-antagonist, on pentagastrin-stimulated acid secretion in healthy subjects.
The purpose of this study is to investigate the effects of a single oral dose of 10 mg of mifentidine, a new H2-receptor antagonist, on unstimulated and pentagastrin-stimulated gastric acid secretion in healthy subjects. The study was carried out in a double-blind randomized, placebo controlled, cross-over design. Ten subjects were given both placebo and active drug, with a wash-out period of at least 3 days. Unstimulated acid secretion was measured in the period between 1 and 1.5 h after drug administration. Immediately thereafter, 2 micrograms/kg/h of pentagastrin was infused intravenously and pentagastrin-stimulated gastric acid secretion was determined for two subsequent hours. The volume of gastric secretion was significantly less after mifentidine than after placebo during the pentagastrin-stimulated period. Acid output was inhibited during unstimulated and pentagastrin-stimulated secretion by mifentidine by 45% and 39% of the placebo values, respectively. No adverse clinical or laboratory effects were noted during the study. The results of this study indicate that mifentidine, given as a single oral dose of 10 mg, inhibits effectively unstimulated and pentagastrin-stimulated acid secretion in healthy subjects.
D000328:Adult; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D010418:Pentagastrin / Q000037:antagonists & inhibitors*
D006635:Histamine H2 Antagonists; D007093:Imidazoles; C039796:mifentidine; D010418:Pentagastrin